سعر مفاسي 100مجم4مل فيال 2024

Mvasi 100 mg/4 ml vial (Amgen; bevacizumab-awwb): bevacizumab biosimilar concentrate for intravenous infusion, 100 mg in 4 ml (25 mg/ml), listed in Egyptian price directories. Same brand/strength presentation as the US Amgen MVASI vial.

• Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment (US MVASI label).Population: AdultsDailyMed (U.S. National Library of Medicine)
• Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment (US MVASI label).Population: AdultsDailyMed (U.S. National Library of Medicine)
• Recurrent glioblastoma in adults (US MVASI label).Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions across indications include epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, back pain and exfoliative dermatitis (see US MVASI label for indication-specific lists).International label, same product · DailyMed (U.S. National Library of Medicine)

• US MVASI label lists no contraindications in section 4.International label, same product · DailyMed (U.S. National Library of Medicine)

• Gastrointestinal perforations and fistula: discontinue for gastrointestinal perforation, tracheoesophageal fistula, Grade 4 fistula, or fistula involving any organ.International label, same product · DailyMed (U.S. National Library of Medicine)
• Surgery and wound healing: withhold for at least 28 days before elective surgery and for at least 28 days after major surgery until adequate wound healing; discontinue for necrotizing fasciitis wound-healing complication.International label, same product · DailyMed (U.S. National Library of Medicine)
• Hemorrhage: severe or fatal hemorrhages have occurred; do not administer for recent hemoptysis; discontinue for Grade 3–4 hemorrhage.International label, same product · DailyMed (U.S. National Library of Medicine)

• Based on animal data and mechanism of action, bevacizumab products may cause fetal harm; limited postmarketing reports describe fetal malformations. Advise pregnant women of the potential risk to a fetus.International label, same product · DailyMed (U.S. National Library of Medicine)
• Advise not to breastfeed during MVASI treatment (US label).International label, same product · DailyMed (U.S. National Library of Medicine)

English text not available for this section.